News and Announcements
Actinogen Receives Offer to Purchase All Less Than Marketable Parcels of Shares
- Published August 17, 2016 4:08PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
16th August 2016, ASX Announcement
The Board of Actinogen Medical Limited (ASX: ACW) (Actinogen or the Company) is pleased to announce that it has received an offer from an Australian financial services licensee to purchase all less than marketable parcels of shares in the Company for $0.0645 per share (Offer).
A less than “marketable parcel” (defined in the ASX Listing Rules as a parcel of shares with a market value of less than $500) will be any shareholding of 8,928 shares or less (Less than Marketable Parcel) on the record date. The record date for the purpose of establishing holders of Less Than Marketable Parcels has been set at close of trade on 15 August, 2016 (Record Date).
As at the Record Date, over 515 of the Company’s approximately 1,864 shareholders held Less Than Marketable Parcels, making up approximately 0.34% of the Company’s fully paid ordinary shares on issue.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
